Duolingo Inc vs Natera Inc. Common Stock — how do they compare? Duolingo Inc trades at $138.28 (market cap $6.55B), while Natera Inc. Common Stock trades at $394 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 8.7× Duolingo Inc's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Duolingo Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Duolingo Inc for 138 Days and Natera Inc. Common Stock for 0 Days on average.
| DUOL | NTRA | |
|---|---|---|
Market Cap | $6.55B | $57.03B |
Volume | 767,658 | 1,131,157 |
Sector | Technology | Health |
52-Week High | $341.08 | $425.64 |
52-Week Low | $90.03 | $179.42 |
Typical Hold Time | 138 Days | 0 Days |
Enterprise Value | $5.33B | $56.18B |
Signals from Pluang's Aura AI — not financial advice
Duolingo (DUOL) trades at $139.73, down 5.42% on the day, as the stock consolidates near key technical support levels. The company demonstrates strong fundamental performance with 2025 revenue reaching $1.04 billion and net income of $414 million, representing a robust 39.9% profit margin. Recent earnings beats and analyst consensus of $142.50 price target suggest underlying strength despite recent price weakness. Technical indicators show a bullish moving average signal with neutral oscillators, while institutional sentiment remains mixed with notable insider selling activity.
Duolingo presents a compelling growth story with exceptional profitability metrics and consistent earnings outperformance. The primary investment opportunity lies in the company's AI-driven platform expansion and strong user growth momentum. Key risks include CEO share liquidations, competitive pressures in edtech, and valuation concerns at current levels. The stock's current discount to consensus target offers potential upside if execution continues.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Duolingo Inc is a mobile learning platform to learn languages and the top-grossing app in the Education category on both Google Play and the Apple App Store. It has three predominant sources of revenue
Read more on DUOL →Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →